<DOC>
	<DOCNO>NCT01555866</DOCNO>
	<brief_summary>This 2-part , open-label study , design evaluate effect renal disease pharmacokinetics BAL4815 ( active isavuconazole moiety ) relative pharmacokinetics healthy subject normal renal function .</brief_summary>
	<brief_title>Study Effect Renal Impairment Pharmacokinetics Isavuconazole .</brief_title>
	<detailed_description>In Part 1 , eligible subject enrol one 2 group base renal function . All subject receive single 1-hour infusion isavuconazole remain confined 4 day . Subjects normal renal function return clinic several outpatient visit 15 day dose . Subjects renal disease complete outpatient visit correspond schedule dialysis date readmitted clinic study Day 15 receive second 1-hour infusion isavuconazole follow normal dialysis procedure remain confined 4 day . ECGs , vital sign , blood draw obtain throughout study safety ass amount study drug body well study drug remove subject undergoing dialysis . In Part 2 , eligible subject enrol one 4 group base renal function . All subject receive single 1-hour infusion isavuconazole remain confined 4 day . Subjects return clinic several outpatient visit 15 day dose . ECGs , vital sign , blood draw obtain throughout study safety ass amount study drug body .</detailed_description>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Subject must weigh least 45 kg body mass index 1835 kg/m2 If female , subject agree sexual abstinence , surgically sterile , postmenopausal use medically acceptable doublebarrier method prevent pregnancy agree continue use method study 28 day final study dug administration . Female subject must lactate pregnant document negative pregnancy test Screening Day 1 If male , subject agree sexual abstinence , surgically sterile , use medically acceptable method prevent pregnancy agree continue use method study 90 day end study The subject good venous access Female subject must donate ovum start Screening throughout study period , 28 day final study drug administration . The subject previous history clinically significant gastrointestinal , neurological , hepatic , pulmonary , metabolic , dermatologic , immunologic , cardiovascular , psychiatric , genitourinary , endocrine , hematological disorder disease , malignancy exclude nonmelanoma skin cancer medical condition would preclude participation study The subject evidence cardiac conduction abnormalities The subject history unexplained syncope , cardiac arrest , unexplained cardiac arrhythmia , torsade de pointes , structural heart disease , family history Long QT syndrome The subject supine systolic blood pressure le 90 great 160 mmHg , diastolic blood pressure le 50 great 90 mmHg , pulse rate le 40 great 100 beat per minute , either Screening Day 1 The subject history consume 14 unit alcoholic beverage per week , history alcohol abuse within past 2 year prior Screening , positive screen alcohol Screening Day 1 . ( NOTE : one unit = 12 ounce beer , 4 ounce wine 1 ounce spirits/hard liquor . ) The subject positive test alcohol drug abuse Screening Day1 , unless expect result due approve concomitant medication subject renal impairment The subject use nicotine patch tobaccocontaining product within 1 month prior Day1 smoker , define great 10 cigarette per week The subject treatment prescription drug complementary alternative medicine within 14 day prior Screening , overthecounter medication within 14 day prior Screening ( exception acetaminophen 2 grams/day ) The subject anticipate inability abstain caffeine alcohol 48 hour prior Day 1 throughout duration study The subject anticipate inability abstain grapefruit , Seville oranges , star fruit , product contain item 72 hour prior Day 1 throughout duration study The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 7 day prior Day 1 The subject vaccinate within last 30 day prior Screening The subject positive test hepatitis C antibody hepatitis B surface antigen Screening know history human immunodeficiency virus The subject know suspected hypersensitivity isavuconazole , azole class compound , component study drug The subject receive experimental agent within 30 day ten halflives , whichever longer , prior Screening The subject significant blood loss , donate one unit ( 450 mL ) blood receive transfusion blood blood product within 60 day donate plasma within 7 day prior Day 1 The subject condition , opinion investigator , preclude subject 's participation trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>isavuconazole</keyword>
	<keyword>BAL4815</keyword>
	<keyword>BAL8557</keyword>
	<keyword>BAL8728</keyword>
</DOC>